129 related articles for article (PubMed ID: 19259551)
1. Molecule of the month. Semagacestat.
Drug News Perspect; 2008 Sep; 21(7):390. PubMed ID: 19259551
[No Abstract] [Full Text] [Related]
2. What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.
Schor NF
Ann Neurol; 2011 Feb; 69(2):237-9. PubMed ID: 21387368
[TBL] [Abstract][Full Text] [Related]
3. What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
Cummings J
Biol Psychiatry; 2010 Nov; 68(10):876-8. PubMed ID: 21035622
[No Abstract] [Full Text] [Related]
4. NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.
Samson K
Ann Neurol; 2010 Oct; 68(4):A9-A12. PubMed ID: 20976761
[No Abstract] [Full Text] [Related]
5. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
6. Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.
Imbimbo BP; Peretto I
Curr Opin Investig Drugs; 2009 Jul; 10(7):721-30. PubMed ID: 19579178
[TBL] [Abstract][Full Text] [Related]
7. In response to "a gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system".
Raybon JJ; Albright CF
Ann Neurol; 2010 Jan; 67(1):143-4; author reply 144-5. PubMed ID: 20186950
[No Abstract] [Full Text] [Related]
8. ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).
Hopkins CR
ACS Chem Neurosci; 2010 Aug; 1(8):533-4. PubMed ID: 22778845
[TBL] [Abstract][Full Text] [Related]
9. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Trechot P; Schmutz JL
Ann Dermatol Venereol; 2013 Oct; 140(10):669-70. PubMed ID: 24090904
[No Abstract] [Full Text] [Related]
10. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Siemers ER; Quinn JF; Kaye J; Farlow MR; Porsteinsson A; Tariot P; Zoulnouni P; Galvin JE; Holtzman DM; Knopman DS; Satterwhite J; Gonzales C; Dean RA; May PC
Neurology; 2006 Feb; 66(4):602-4. PubMed ID: 16505324
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's failure raises questions about disease-modifying strategies.
Extance A
Nat Rev Drug Discov; 2010 Oct; 9(10):749-51. PubMed ID: 20885394
[No Abstract] [Full Text] [Related]
12. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.
Carlson C; Estergard W; Oh J; Suhy J; Jack CR; Siemers E; Barakos J
Alzheimers Dement; 2011 Jul; 7(4):396-401. PubMed ID: 21784350
[TBL] [Abstract][Full Text] [Related]
13. Semagacestat for treatment of Alzheimer's disease.
Pomara N
N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152269
[No Abstract] [Full Text] [Related]
14. Semagacestat for treatment of Alzheimer's disease.
Gupta VB; Gupta VK; Martins R
N Engl J Med; 2013 Oct; 369(17):1660-1. PubMed ID: 24152268
[No Abstract] [Full Text] [Related]
15. Semagacestat for treatment of Alzheimer's disease.
Doody RS; Aisen PS; Iwatsubo T
N Engl J Med; 2013 Oct; 369(17):1661. PubMed ID: 24152267
[No Abstract] [Full Text] [Related]
16. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Henley DB; May PC; Dean RA; Siemers ER
Expert Opin Pharmacother; 2009 Jul; 10(10):1657-64. PubMed ID: 19527190
[TBL] [Abstract][Full Text] [Related]
17. [Gamma-secretase inhibitors and modulators].
Iwai A
Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():83-7. PubMed ID: 22755160
[No Abstract] [Full Text] [Related]
18. Semagacestat Is a Pseudo-Inhibitor of γ-Secretase.
Tagami S; Yanagida K; Kodama TS; Takami M; Mizuta N; Oyama H; Nishitomi K; Chiu YW; Okamoto T; Ikeuchi T; Sakaguchi G; Kudo T; Matsuura Y; Fukumori A; Takeda M; Ihara Y; Okochi M
Cell Rep; 2017 Oct; 21(1):259-273. PubMed ID: 28978478
[TBL] [Abstract][Full Text] [Related]
19. Lessons from a failed γ-secretase Alzheimer trial.
De Strooper B
Cell; 2014 Nov; 159(4):721-6. PubMed ID: 25417150
[TBL] [Abstract][Full Text] [Related]
20. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.
Rosenberg PB; Lanctôt KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R
J Alzheimers Dis; 2016 Aug; 54(1):373-81. PubMed ID: 27567808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
